Sugemalimab approval in China makes it only second drug approved globally for ENKTL: GlobalData EP News Bureau Nov 20, 2023 GlobalData forecasts sugemalimab to generate sales of $31 million (patient-based forecast) by 2030 for T-cell lymphomas in China
COVID-19 vaccine key conversation driver for Pfizer among Twitter influencers during Q4 2020–… EP News Bureau Jan 6, 2021 Pfizer partnered with CStone to develop and commercialise oncology therapies of CStone in China.
